Novel antitubercular agent, exerting growth inhibition of Mtb during parasitism of host macrophages

Novel anti-SARS-CoV-2 agent, displaying in vitro antiviral activity with IC 50 0.016 µM and Mpro inhibition activity with IC 50 0.013 µM, showing potent activity against human TMPRSS2 and furin enzymes with IC 50 0.05, and 0.08 µM, respectively

Novel antioxidant, binding copper in a unique manner compared to other chelates proposed to treat Alzheimer's disease and protecting HT-22 neuronal cells from cell death induced by Aβ + copper(II)

Novel anti-MERS-CoV agent against virus-infected Huh7 cells

Novel idebenone analog, demonstrating significantly higher potency ex vivo, and significantly lower cytotoxicity, than idebenone in the treatment of Leber's Hereditary Optic Neuropathy (LHON)

Novel antileishmanial agent, strongly inhibiting recombinant CYP51 from L. donovani, displaying activity against L. donovani intracellular amastigotes with an IC50 value of 0.53 μM

Novel antileishmanial agent against L. amazonensis promastigotes (IC 50 = 15.52 ± 3.782 μM) and intracellular amastigotes (IC 50 = 4.10 ± 1.136 μM), 50% cytotoxicity concentration at 84.01 ± 3.064 μM against BALB/c peritoneal macrophages, and 20.49-fold s

Novel antifungal agent, inhibiting C. neoformans growth at submicromolar levels, being effective against fluconazole-resistant C. neoformans and a clinical strain of C. gattii, and being not antagonistic with currently approved antifungal

Novel broad-spectrum antifungal agent, also exhibiting good fungicidal activity against both fluconazole-sensitive and -resistant Candida albicans cells and having potent inhibition activity against Candida albicans biofilm formation and hyphal growth, in

Novel inhibitor of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter (PCFT) over the reduced folate carrier (RFC)

Novel inhibitor of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter (PCFT) over the reduced folate carrier (RFC)

Novel covalent anti-cancer toxin, targeting β-tubulin and covalently modifyng Cys239 within the colchicine binding site

Novel anticancer agent, showing most significant anti-cancer activity against prostate cancer cells with IC50 values of 8.8 µM and 9.5 µM in PC-3 and DU-145 cells, respectively

Novel Potent and Nontoxic Antibiotic Adjuvant

Analogue of the marine sponge natural product oroidin, suppresses biofilm formation and enhancing control of copper-resistant Xanthomonas euvesicatoria on pepper

Novel dose-dependent antiangiogenic agent

Novel highly potent orally bioavailable antiallergic agent, effectively suppressing mast cell degranulation in a dose-dependent manner (IC50, 2.54 nM for RBL-2H3 cells; 48.28 nM for peritoneal mast cells (PMCs))

Novel multitarget directed anti-Alzheimer agent, showing an IC 50 value of 0.56 ± 0.02 μM for AChE and an IC 50 value of 1.17 ± 0.09 μM for BuChE

Novel anti-AD agent, integrating Aβ-interacting and metal-binding fragments in a single molecular framework, exhibiting significant antioxidant activity and metal chelating ability, and also rescuing neuroblastoma N2A cells from Cu -induced Aβ neurotoxici

Novel Broad-Spectrum Serine β-Lactamase Inhibitor, Strongly Potentiating Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter baumannii

Novel Metallo-β-lactamase Inhibitor with Potential for Clinical Use in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae

Antimitotic antibiotic with antitumor, antiprotozoal, and antifungal activities

Natural inhibitor of NADH:ubiquinone oxidoreductase

Novel Potent and Selective DYRK1 Kinase Inhibitor

Novel potent DYRK1A Kinase Inhibitor

Novel activator of nuclear factor-erythroid-related factor 2 (Nrf-2)

Novel inducer of autophagic cell death through regulating PI3 kinase class III/beclin 1/Atg-related proteins in cisplatin-resistant CAR human oral cancer cells

Peptide hormone that causes vasoconstriction and an increase in blood pressure

Novel angiogenesis agent, showing better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells, significantly increasing the angiogenic potential of vascular endothel

Novel anticancer agent against metastatic Castration resistance and neuroendocrine variant prostate cancers (mCRPC/NEPC), exhibiting synergistic anticancer effect in combination with standard therapy docetaxel and cabazitaxel in mCRPC/NEPC, upregulating H